EP300 CBP Modulation Compounds for Leukemia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is an unmet need for new compounds that can effectively modulate EP300 or CBP, as current inhibitors are not approved for human treatment, and these proteins are associated with various diseases including acute myeloid leukemia and multiple myeloma, where their inhibition has shown therapeutic potential.
Innovation Solution
Development of novel compounds, as described in Formula I, which can modulate EP300 or CBP, including pharmaceutical compositions and methods for treating diseases mediated by these proteins, offering a new therapeutic approach.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If EP300 or CBP inhibition is used to treat diseases, then therapeutic effect is improved, but no approved inhibitors are available for human treatment
Solution Approach 1:
The patent segments the therapeutic approach by developing a series of compound analogs with different structural modifications (Formula I variations with different R groups, substituents, and core structures). This allows systematic optimization of inhibitor properties to achieve reliable therapeutic effects while addressing the lack of approved inhibitors through methodical compound development.
Solution Approach 2:
The patent applies parameter changes by modifying chemical structure parameters (molecular weight, lipophilicity, hydrogen bonding capacity, steric bulk) of the EP300/CBP inhibitors to optimize their therapeutic profile. This systematic variation of molecular parameters enables the development of compounds with improved efficacy and safety for human treatment.
2Adaptability or versatility
If novel compounds are developed to modulate EP300 or CBP, then new therapeutic options are provided, but compound complexity increases
Solution Approach 1:
The patent creates universal inhibitor compounds (Formula I) that can modulate both EP300 and CBP proteins, providing multi-functional therapeutic activity. These compounds serve multiple purposes: they inhibit both target proteins, can be used for various diseases associated with these proteins, and provide a platform for further optimization, thereby reducing overall complexity while increasing versatility.
Solution Approach 2:
The patent uses bromodomain-containing proteins as intermediaries to understand the binding mechanism of the inhibitors. By studying how these compounds interact with bromodomains (which read acetyl marks), researchers can optimize the inhibitors' ability to modulate EP300/CBP activity, providing a systematic approach to managing compound complexity.
Data Source
AI summary
Disclosed are compounds of Formula I:or a pharmaceutically acceptable salt, a solvate, a tautomer, a stereoisomer or a deuterated analog thereof, wherein A1, A2, A3, A4, R4, X1, X2, and X3 are as described in any of the embodiments described in this disclosure; compositions thereof; and uses thereof.